Biotechs hit 3Q with coolers full of cash; plus Distillery on Tap: a BioCentury podcast
The slowdown in biopharma financings and M&A has provided some buysiders a welcome relief from the breakneck pace of the past year and a half, and with many companies’ coffers full, the pressure to raise money is low. In the latest BioCentury This Week podcast, BioCentury’s editors discuss the 3Q21 Financial Markets Preview, as well as the latest in translational news and a neurology deal for GSK.
Biotech has finally hit a pause in the market after a cash-rich 15-month ride, says Associate Editor Stephen Hansen, who notes that companies may hardly notice as that ride has left the sector flush with capital. Hansen does say that the pace of IPOs is unlikely to slow given that insiders continue to drive the deals even as follow-on financings have fallen from 125 in Q1 to fewer than 40 last quarter.
BioCentury This Week’s new monthly feature Distillery on Tap highlights Senior Editor Karen Tkach Tuzman’s picks among the latest translational news out of academia. BioCentury scans about 30 top biomedical journals for papers with immediate translational relevance, with a focus on either new targets for an indication, or new technology to get at established targets.